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Division of Thoracic & Cardiovascular Surgery, Hannover Medical School, Hannover, Germany
Objective. To review our experience of using cryopreserved allografts for in situ reconstruction in the presence of infection
involving the aorta, iliac or femoral arteries.
Design. Retrospective clinical study.
Methods. From 3/2000 to 8/2003 all patients with mycotic aneurysms or secondary infection following earlier prosthetic
replacement were treated with cryopreserved human allografts. Forty-two patients, 39 (93%) with a prosthetic graft infection and
3 (7%) with a mycotic aneurysm of the abdominal aorta were treated. Six (14%) had aorto-enteric fistulas, 5 (12%) had ruptured
aneurysms, and 2 also had vertebral destruction. The median follow-up time was 20 months (range 1–42 months).
Results. Thirty-day mortality was 14%. Three patients died due to multi-organ failure, two patients died from hypovolaemic
shock due to allograft rupture and one from rupture of the native aorta. The overall mortality was 24% (four additional patients).
Graft patency was 100% at 30 days and 97% at follow up in the survivors. The mean actuarial survival time was 32 months (95%
CI ¼ 27–37 months).
Conclusions. Cryopreserved allografts for the in situ reconstruction of infected arteries or grafts have acceptable intermediate
results.
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Introduction
The traditional approach to arterial reconstruction in
the presence of primary or secondary infection is
complete excision and debridement, plus extra-
anatomic or in situ prosthetic bypass grafting.1 However,
the outcome is poor regarding mortality, limb loss and
eradication of infection.2 The use of biological materials
i.e. autologous vein, or human allografts, which may
have better resistance to infection, has been proposed as
the method of choice for in situ reconstruction.1–4 The
purpose of this study was to analyse the outcome of in
situ arterial reconstructions, using cryopreserved homo-
grafts, in cases of major infection involving the aorta,
iliac or femoral arteries.
Patients and Methods
Patients
From 3/2000 to 8/2003 42 patients (29 men and 13
women, median age 66, range 40–89 years) presenting
with vascular infections were treated using cryo-
preserved human allografts for in situ reconstruction.
The indications for surgery were prosthetic graft
infection in 39 patients (93%), combined with a con-
comitant aorto-enteric fistula in six patients (14%), and
primary mycotic aneurysms in three patients (7%).
Five patients (12%) presented with a ruptured aneurysm
and acute haemorrhage (Table 1). The preoperative
diagnosis of graft or arterial infection was made by
ultrasound and computed tomography confirming
peri-graft fluid or gas formation and/or positive
microbiology from open wounds. The direct aspira-
tion of fluid was avoided preoperatively. Graft infec-
tion occurred from 7 days to 17 years (median
35 month) following the initial vascular operation.
Three patients presented with mycotic aneurysms, one
in aortic and two in femoral position. One patient with
a femoral aneurysm was i.v. drug dependent and had
no preoperative CT or ultrasound scan as he was
admitted with an acute rupture. All patients presented
with peripheral embolisation, fever and leukocytosis.
The microbiological investigation of vessel specimens
reported Staphylococcus aureus in all positive cases
(Table 1).
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Table 1. Pathology, bacteriology and graft configuration in 42 patients who received a cryopreserved human allograft
Original graft/infection
site
Microbiology Allograft configuration Additional pathology and procedures
(a) Graft infections ðn ¼ 39Þ
Aortic tube graft (3) Escherichia coli (1), Proteus mirabilis (1), no growth
(1)
Descending aorta (2), aorto-biiliac (1) Aorto-enteric fistula, small bowel segment
resection (2), vertebral destruction (1)
Aorto-iliac (1) No growth (1) Iliac arteries (1) Ruptured aneurysm (1)
Aorto-femoral/-profundal
(5)
ORSA (1), no growth (4) Iliac arteries (4), femoral arteries (1) Rectus femoris muscle flap (1)
Aorto-biiliac (6) Bacterioides spp. (1), Candida albicans (1), E. coli
(1), Enterococcus faecalis (1), Gram negative rods
(1), Gram positive cocci (2), Salmonella (1)
Aorto-biiliac (5), iliac artery, incomplete excision
(1)
Aorto-enteric fistula, small bowel segment
resection (2), vertebral destruction (1)
Aorto-
bifemoral/profundal (14)
Citrobacter koseri (1), Corynebacterium (1), E. faecalis
(4), E. coli (1), Gram positive cocci (6), Gram
negative rods (1), ORSA (1), Pseudomonas
aeruginosa (1), S. aureus (2), Moraxella spp. (1), no
growth (5)
Femoral/iliac arteries, incomplete excision (7),
aorto-bifemoral/profundal (7)
Aorto-enteric fistula, small bowel segment
resection (2), ruptured aneurysm (2), rectus
femoris muscle flap (1)
Femoro-distal (8),
prothesio-distal (1)
C. albicans (2), Corynebacterium (1), Gram positive
cocci (1), E. coli (1), E. faecalis (1), ORSA (2), P.
aeroginosa (1), S. aureus (1), no growth (6)
Iliac arteries (9) D2 amputation (1)
Femoro-femoral (1) No growth (1) Iliac arteries (1)
(b) Mycotic aneurysms ðn ¼ 3Þ
Aortic (1) S. aureus (1) Aorto-biiliac (1)
Common femoral artery (2) E. coli (1), S. aureus (2), ORSA (1), P. aeruginosa (1) Iliac arteries (2) Ruptured aneurysm (2), rectus abdominis muscle
flap (1)
ORSA, oxacillin resistant S. aureus.
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Surgical technique
Arterial segments were harvested from multi organ
donors. Harvesting, preparation, antibiotic treatment,
cryopreservation, and procurement of human allo-
grafts are largely standardised and have been
described previously.3,5 Fresh human allografts or
animal xenografts were not used in this study.6
Thirty-four patients (81%) were treated with com-
plete graft excision and an extensive peri-vascular
debridement. Generally, the type of homograft used
corresponded to the removed prosthesis in length and
shape. In one patient, an infected tube graft was
replaced with a bifurcated allograft (Fig. 1(a)). The
following reconstructions were performed: tube graft
ðn ¼ 2Þ; aorto-biiliac ðn ¼ 6Þ; aorto-bifemoral/profun-
dal ðn ¼ 7Þ; aorto-iliac ðn ¼ 1Þ; aorto-femoral/profundal
ðn ¼ 5Þ; and iliaco-femoral (n ¼ 12). A local debride-
ment of the infectious focus with only ‘limited’
excision of the infected graft was performed in eight
patients (19%), where the problem was clearly limited
to only a small portion of the graft, e.g. at the site of the
femoral anastomosis. In these cases the anastomosis
between the intact non-infected graft and allograft was
always completed in a proximal clean operating field
through a separate incision and the distal end of the
allograft then pulled through to the contaminated field
using the distal end of the prosthetic graft. Infected
prosthetic material and wound fluid was cultured for
microorganisms.
Allografts were sutured end-to-end to the normal
aorta, iliac or femoral artery or to a macroscopically
non-infected prosthetic segment with continuous non-
absorbable 3 – 0 to 5 – 0 polypropylene sutures,
depending on graft diameter. Prior to implantation
of the allografts the side branches were oversewn
using 5/0 polypropylene and limbs were extended,
using for example the internal iliac branches, to give
adequate length to reach the groin, if required.
Metallic clips and ligatures were avoided. All grafts
were externally impregnated with neomycin and
fibrin glue following implantation.
Additional surgical procedures such as muscle
flaps (in case of groin wound dehiscence) or omental
wrapping (in case of large areas of debridement, or
vertebral destruction) were performed to protect the
graft and improve healing. Wounds were drained with
multiple suction drains.
Peri-operative management and follow-up
CT and duplex ultrasound scanning was performed
preoperatively in every patient except for those
needing emergency surgery for acute rupture and
bleeding. Patients received extensive antibiotic cover
according to cultures of blood, and pre- or intra-
operative specimens for a minimum of two weeks.
Following this period, a specific antibiotic treatment
was continued for a minimum of four weeks or longer,
depending on clinical and laboratory parameters.
Antibiotics used included metronidazole, ciprofloxa-
cin, amoxicillin, teicoplanin, and vancomycin. Prior to
specific treatment or in those cases where no positive
culture was obtained, patients received clindamycin or
vancomycin.
Clinical follow-up and ultrasound graft surveil-
lance was performed prior to hospital discharge, at 3
months, and in June 2003. Graft problems, if present,
were further elucidated by means of colour duplex
scans, CT scans, MRI scans, MRI angiograms, or digital
subtraction angiography. In addition, all survivors
except two (one aged over 90, one in prison) were seen
in the outpatients department.
Statistical analysis
Continuous variables are expressed as medians and
ranges. SPSS 10.0 for Windows was used for Kaplan–
Meier survival analysis.
Results
The median postoperative ICU stay was 3 days (0–41
days) and the median postoperative hospital stay was
14 days (9–132 days). The median postoperative
follow-up period was 20 months (1–42 months). The
mean actuarial survival time was 32 months (95%
CI ¼ 27–37 months).
Allograft disintegration at the site of the anastomo-
sis or side branch sutures occurred in four patients
(10%) due to inferior allograft quality or size mis-
matches. In these cases new allograft patch enhanced
sutures were used following resection of the failed
anastomosis. In the group of survivors, further
surgical procedures were needed in 10 patients
because of persistent abdominal infections requiring
revisions due to aorto-enteric fistulas (three patients)
or disturbed groin wound healing (six patients). One
patient presented with a recurrent aorto-enteric fistula
after he had already left the intensive care unit. The
proximal anastomosis was revised using homograft
patch enhanced polypropylene sutures. The remain-
ing four patients with aorto-enteric fistulas did well.
In all cases, the vascular axis could be reconstructed
in situ. Primary patency of the grafts was thus 100%
initially (Fig. 1(b)). In the survivors (32 patients), there
were two patients (6%) with severe vascular problems
(Table 2). One presented himself too late to hospital
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following thrombosis of his prothetic-femoral graft
resulting in lower limb amputation. The patient
with the recurrent aorto-enteric fistula was read-
mitted with claudication 2 month after revision of
the anastomosis. Intra-arterial digital subtraction
angiography revealed a haemodynamically signifi-
cant stenosis of the proximal anastomosis between
the aorta and the bifemoral homograft. The patient
was successfully treated with percutaneous trans-
luminal angioplasty and stent application. Two
additional patients have non-significant stenoses
of the femoral/profundal anastomosis and are
followed up in 3 monthly intervals in our out-
patients department. Secondary patency, therefore,
is determined to be 97%.
The 30-day mortality was 14% (six patients). Three
patients died due to multi organ failure or septic
shock on postoperative day (POD) 13, 18, and 21.
Postmortem examination revealed intact homografts
in all three patients and an intact bowel reconstruction
in the one patient who had had an aorto-enteric fistula.
Despite further emergency surgery two patients died
from hypovolaemic shock due to allograft rupture
(POD 7 and 12) and one from rupture of the native
aorta proximal to the allograft replacement (POD 27)
(Table 2). Subsequent mortality was 10% (four
additional patients) resulting in an overall mortality
of 24%. One patient with a prolonged intensive care
unit stay after aortic homograft implantation died
on POD 41 due to sepsis. His relatives refused
a postmortem examination. Another patient was
readmitted with a groin infection that did not expose
the graft. Despite debridement and vacuum drain
therapy the wound and renal function deteriorated
and he died from a myocardial infarction. According
to their general practitioner the remaining two patients
both had a fatal cardiac arrest that was not related to
the vascular operation (POD 96 and 120) (Table 2).
Fig. 1. Intra-operative view (a) and computed tomography scan reconstruction (b) after aorto-bi-iliac in situ replacement with
a cryopreserved homograft made from an infrarenal aortic segment and two iliac arteries.
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Discussion
Prosthetic vascular graft infections have become a
serious problem, particularly when the aorta is
involved. Most graft infections are caused by inocu-
lation of bacteria at the time of surgery, despite peri-
operative antibiotics. One to six percent of prosthetic
grafts are affected.7 The poor outcome is mostly due to
multi organ failure, sepsis, suture line disruption and
gastrointestinal bleeding when aorto-enteric fistula or
erosion is associated.8,9 Following thorough debride-
ment, two surgical methods of arterial reconstruction
have been proposed for the treatment of graft
infections: extra-anatomic repair or in situ repair with
the use of fresh or cryopreserved human arterial or
venous allografts, arterial or venous autografts,
prosthetic grafts, and animal xenografts.10 However,
the published results are difficult to compare due to
the small number of grafts and the large number of
variables involved. In addition, there are no random-
ised trials. In particular, the indications for in situ
reconstruction using cryopreserved arterial homo-
grafts are not commonly agreed.11
Our results for early and intermediate mortality, as
well as reintervention rates, are comparable to those
presented by other groups.2,11 However, Gibbons et al.
described only one peri-operative death and no limb
loss after reconstruction with autologous femoro-
popliteal veins in a series with a follow-up period
from one month to five years. One difference com-
pared to our patient group is the absence of aorto-
enteric fistula in their patients, which is commonly
associated with a high mortality.12 – 14 In our series, the
one patient (of six) with an aorto-enteric fistula who
died, had an intact vascular graft and bowel anasto-
mosis at postmortem examination.
The development of graft stenoses is well docu-
mented following prosthetic and biological replace-
ment of arterial segments.1,2,12 In our series, the one
anastomotic stenosis of the infrarenal aorta was not
diagnosed prior to hospital discharge. It may, there-
fore, be assumed that it was not related to the revision
of the anastomosis but to intimal hyperplasia occur-
ring later. Follow-up is thus required for all patients
with allograft arterial reconstructions, as stenoses can
often be treated by endovascular means.1
The alleged superior resistance of allografts to
infection could be related to their viability that allows
improved transfer of antibiotics and immunocom-
petent cells through the wall and into the peri-graft
space.2 Furthermore, allografts may have an enhanced
anti-microbial activity compared to conventional
grafts, since they are stored in antibiotic solution and
in our practice are impregnated with neomycin fibrin
glue.15 – 17 However, there is no level one evidence of
better resistance to infection or patency of allografts
compared to prosthetic grafts.10
The limited availability and high cost of allografts
may be overcome with improved cooperation on a
European level regarding allocation, donor manage-
ment, safety tests, and legal aspects. Additional
research is required to detect the effect of different
preparation methods, antibiotic storage solutions,
cryopreservation protocols, potential modifications
(e.g. decellularisation), and long-term storage on
allograft quality and performance.18
There are several limitations of our study. The study
was retrospective, the number of patients included
was low and the observation period rather short,
compared, for example, to the data of Szilagyi,
especially with regard to long-term outcome.19
Because of the variety of surgical procedures prior to
the infection and indeed those performed for the graft
infection, indications for surgery, implantation sites,
Table 2. Major complications after in situ arterial reconstruction with cryopreserved human allografts
Surgical procedure Comorbidities Event Microbiology* POD Complication
Tube graft CAD, PAD Rupture of native aorta No growth 27 Death
Tube graft CAD, DM, AEF, VB MOF, sepsis E. coli 41 Death
Aorto-biiliac graft CAD MOF, sepsis Gram positive cocci 18 Death
Aorto-biiliac graft CAD, PAD, CRF MOF, sepsis E. coli 21 Death
Aorto-biiliac graft CAD, PAD, DM MOF, sepsis Gram negative rods 13 Death
Aorto-biiliac graft PAD Allograft rupture (iliac limb) C. albicans, E. fecalis 12 Death
Aorto-biprofundal graft PAD Allograft rupture (iliac limb) S. aureus 7 Death
Aorto-femoral graft CAD, CAD Myocardial infarction No growth 96 Death
Femoro-distal graft CAD, PAD, DM Myocardial infarction Gram positive cocci 180 Death
Prothesio-femoral graft† CAD, PAD, DM, CRF Myocardial infarction S. aureus 120 Death
Aorto-bifemoral graft AEF Proximal anastomotic stenosis S. aureus, E. faecalis 60 PTA, stent
Prothesio-femoral graft† CAD, CRF Graft thrombosis No growth 810 Leg amputation
CAD, coronary artery diease; PAD, peripheral artery disease; DM, Diabetes mellitus; AEF, aorto-enteric fistula; VB, vertebral
destruction/abscess; CRF, chronic renal failure; MOF, multi organ failure; PTA, percutaneous transluminal angioplasty.
*At the time of surgery for graft infection.
†Limited excision.
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different antibiotic or anticoagulation treatments and
the requirement of additional surgery, a comparative
analysis of our data is difficult. However, the use of
cryopreserved allografts for in situ reconstruction of
infected arteries or grafts seems to have acceptable
early and intermediate results.
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